Introduction
It is important to note that Guillain-Barré syndrome is an acute autoimmune disorder that comprises a class of acute conditions of the peripheral nervous system. It is characterized by muscle weakness at the beginning of the disease due to the lesion of the sensory fibers (Uncini et al., 2020). Peculiarities of pathophysiology and clinical distribution of weakness in the extremities and cranial nerves characterize each variant of disorders. Therefore, it is essential to determine the main symptoms of the disease, methods of treatment, mortality rate, and prognosis.
Pathophysiology
Guillain-Barré syndrome is the most common of the acquired influenza neuropathies; several varieties exist. In some cases, demyelination prevails, while in others, the axon is affected. Although the reason for Guillain-Barré syndrome is not completely comprehended, it is considered to be autoimmune. This is connected with the condition that about two-thirds of patients have Guillain-Barré syndrome five days to three weeks after an infection, operation, or vaccination. In addition, infection is a trigger factor in more than 50% of patients (Uncini et al., 2020, p. 278).
It is essential to highlight that the most common pathogens include Campylobacter, intestinal viruses, herpes viruses (such as cytomegalovirus and Epstein-Barr virus), as well as species of the genus Mycoplasma. Thus, stimulation of the cellular and humoral intrinsic immunity lies at the heart of the pathophysiology of the illness (Uncini et al., 2020). This originates from the development of autoantibodies that specifically target gangliosides and glycolipids, leading to the creation of circulating immune systems that attack the peripheral nerves and roots.
Signs and Symptoms
Most patients with Guillain-Barré syndrome are dominated by flaccid paresis. Moreover, the proximal muscles are affected significantly, and sensory disturbances are less pronounced. In general, almost symmetrical painful muscle weakness with paresthesias typically spreads from the legs and then affects the arms.
Still, in some cases, the paresis begins in the arm or head muscles. In 90% of cases, weakness generally reaches its maximum at 3 to 4 weeks after the onset of illness (Shahrizaila et al., 2021, p. 1214). While deep tendon reflexes drop out, sphincter function is usually not impaired. The weakness remains unchanged for varying periods, usually for several weeks, and then resolves.
In addition, in more than half of severe cases, the muscles of the facial and oropharynx are injured. There may be the development of dehydration and malnutrition. In 5-10% of cases, tracheal intubation and ventilatory ventilation are required due to paralysis of the respiratory muscles (Shahrizaila et al., 2021, p.1215). Moreover, some persons develop severe, life-threatening autonomic nervous dysfunction with fluctuations in blood pressure, abnormal antidiuretic hormone secretion, and arrhythmias. In the unusual variant, Fischer syndrome or Miller-Fischer syndrome, ophthalmoplegia, ataxia, and areflexia may occur.
Diagnosis and Treatment
Guillain-Barré syndrome is challenging to diagnose because some other pathologies can cause similar symptoms. If patients experience signs of this condition, such as numbness or weakness, they should schedule an appointment with a neurologist. The doctor should prescribe electroneuromyography, magnetic resonance imaging (MRI) of the brain, MRI of the cranial nerves, and several laboratory tests (Zaeem et al., 2019). Such procedures are performed if patients complain of difficulty breathing and are unable to move their limbs or faces. In such cases, they require urgent medical attention, and the person needs to be transported to a hospital as soon as possible.
Additionally, two tests may be performed at the hospital to assess how well the nerves are functioning. The first is electroneuromyography, in which thin needles are injected into the muscles, and an electrocardiogram is obtained to observe how they respond to the activation of nearby nerves. The second is the nerve conduction study, in which small disks are attached to the skin and small electrical discharges are applied to stimulate the nerves, allowing for the recording of the rate at which signals propagate through them (Zaeem et al., 2019). In patients with Guillain-Barré syndrome, these tests usually indicate that the signals are not flowing correctly through the nerves.
Afterward, a lumbar puncture should be performed as part of the diagnosis. A lumbar puncture is a procedure in which some fluid is taken from the spinal cord. The fluid sample will be tested for diseases that can cause symptoms similar to Guillain-Barré syndrome, such as a spinal infection (Zaeem et al., 2019). Finally, an MRI of the brain will be necessary to exclude tumor masses, and an MRI of the cranial nerves will be performed to check the condition of the cranial nerves in the brain.
Therefore, most patients with Guillain-Barré syndrome are treated as hospitalized individuals. The primary therapies include the administration of intravenous immunoglobulin, a donor blood-based treatment that helps control the immune system. Additionally, plasmapheresis, a process in which blood is filtered to remove harmful substances that attack the nerves, may also be applied (Zaeem et al., 2019). Additional treatments include intramuscular or intravenous injections of painkillers and relaxants.
There is a constant need for procedures to support bodily functions, such as the use of a breathing apparatus or a feeding tube. Most patients require hospitalization for weeks to months during an acute illness. In a hospital setting, a patient with a severe attack of the disease may need additional procedures (Zaeem et al., 2019). These include artificial respiration in cases of difficulty breathing, a feeding tube, analgesics, and regular massages to prevent pressure sores and maintain joint tone.
Mortality, Morbidity, and Prognosis
Guillain-BarréGuillain-Barré syndrome is currently the most uncommon cause of acute peripheral palsy in almost every country in the world. This is one of the top seven priority research areas in world neurology and is included in the European list of orphan diseases. The incidence is 1-2 cases per 100,000 population per year in children (Yoon et al., 2019, p. 10). It should be mentioned that Guillain-Barré syndrome is fatal in less than 2% of cases.
Most cases improve after a few months, but residual weakness persists for approximately three years in about 30% of adults and a higher proportion of children (Yoon et al., 2019, p. 10). The terminal defects may require vocational retraining, orthopedic correction, or surgery. After early enhancement, in some cases, individuals progress to chronic inflammatory demyelinating polyneuropathy.
Conclusion
Therefore, Guillain-Barré syndrome usually begins as an ascending, relatively symmetrical flaccid paresis. The first step is to make a differential diagnosis with other diseases that present with similar symptoms. Guillain-Barré syndrome is often preceded by an infection, which may be bacterial or viral. The initial signs of Guillain-Barré syndrome typically include weakness or a tingling sensation, which usually begins in the legs. Furthermore, a medical examination requires a professional opinion and analysis, and treatment often involves inpatient hospitalization. The majority of patients are successfully cured, even in the most severe cases of Guillain-Barré syndrome.
References
Shahrizaila, N., Lehmann, H. C., & Kuwabara, S. (2021). Guillain-Barré syndrome. The Lancet, 397(10280), 1214-1228.
Uncini, A., Notturno, F., & Kuwabara, S. (2020). Hyper-reflexia in Guillain-Barré syndrome: Systematic review. Journal of Neurology, Neurosurgery & Psychiatry, 91(3), 278-284.
Yoon, B. A., Bae, J. S., & Kim, J. K. (2019). Recent concepts of Guillain-Barré syndrome. Journal of the Korean Neurological Association, 37(1), 8-19.
Zaeem, Z., Siddiqi, Z. A., & Zochodne, D. W. (2019). Autonomic involvement in Guillain–Barré syndrome: An update. Clinical Autonomic Research, 29(3), 289-299.